GRFS Grifols SA
Company Analysis
Latest News
Grifols Lifts Q3 Profit 28%, Driven by Biopharma Growth
Grifols reported third-quarter 2026 revenue of EUR 2.04 billion, up 8.4% at constant currency. Net profit rose 27.9% to EUR 162 million. Revenue for the first...
🟢 Grifols is trading 4.44% up amid broader U.S. market gains
Grifols is trading at $8.46, up 4.44%, amid broader U.S. market gains. - No company-specific announcement explaining the November 2 move was identified. -...
🟢 Grifols is trading 4.17% up today amid oil retreat and broad market gains
Grifols is trading 4.17% up at $7.88 on October 26, 2026, with broader U.S. market gains providing a supportive backdrop; no fresh company-specific catalyst...
🟢 Grifols rises 4.0% — Biotech Sector Rallies on Positive Clinical Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Grifols SA is trading 4.01% up in pre-market
GRFS is trading at $7.53, up 4.01% in pre-market.
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on September 28, 2026
Consensus estimates for Grifols SA anticipate Q2 2026 revenue of $2.07 billion and an EPS of $0.27, while the stock currently trades at $10.45 compared to an...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on September 21, 2026
Analysts expect Grifols SA to report Q2 2026 revenue of approximately $1.95 billion and earnings per share of $0.27, with the stock currently trading near...
🟢 Grifols is trading 8.7% up in after-hours trading with no confirmed company-specific catalyst
Grifols is trading at $8.00, up 8.70% in after-hours trading despite no confirmed company-specific catalyst. - No confirmed September 15, 2026 announcement,...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on September 14, 2026
For the second quarter of 2026, analysts expect Grifols SA to report consensus revenue of $2.16 billion and an EPS of $0.27, with the current stock price of...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on September 07, 2026
Wall Street analysts expect Grifols SA to report Q2 2026 revenue of $2.23 billion and earnings of $0.27 per share, while the stock currently trades at $7.80...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 31, 2026
Grifols is expected to report Q2 2026 revenue of $2.17 billion and an EPS of $0.27, with the stock’s current price of $8.25 trading significantly below the...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 24, 2026
Grifols SA is expected to report Q2 2026 revenue of $2.17 billion and an EPS of $0.27, while the stock currently trades around $8.25—well below the average...
🟢 Grifols rises 5.0% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 17, 2026
Grifols SA is expected to post Q2 2026 revenue of $2.01 billion and EPS of $0.27, with its current share price of $8.45 sitting significantly under the $12.10...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
For the second quarter of 2026, analysts anticipate Grifols to report a consensus revenue of $2.17 billion and an EPS of $0.27, while the current ADR price of...
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on August 03, 2026
Grifols is expected to report Q2 2026 revenue of $2.06 billion and EPS of $0.27, with the stock currently trading at $9.45 against an average analyst price...
🔴 Grifols is trading 4.4% down today on potential profit-taking
Grifols is trading at $7.84 (down 4.4%) today as the stock faces downward pressure despite a lack of fresh, company-specific headlines. • The move follows a...
Grifols Profits Surge 29%, Driven by Strong Biopharma Demand
Grifols reported a 28.7% increase in net profit to €227 million for the first half of 2026. Revenues rose 2.6% at constant currency to €3.57 billion. The...
🟢 Grifols is trading 4.25% up today on continued idiosyncratic strength
Grifols is trading at $8.34 (+4.25%) in pre-market, extending its upward momentum following a 3.23% gain on July 28. • The move appears driven by...
🟢 Grifols is trading 4.1% up today, defying broader biotech sector weakness
Grifols is trading 4.1% up at $8.07 on above-average intraday strength despite a lack of clear company-specific catalysts. • The move stands out as the...